Irene Ghobrial
#124,900
Most Influential Person Now
American-Egyptian physician and academic
Irene Ghobrial's AcademicInfluence.com Rankings
Irene Ghobrialphilosophy Degrees
Philosophy
#6622
World Rank
#9684
Historical Rank
Logic
#3762
World Rank
#4967
Historical Rank
Download Badge
Philosophy
Irene Ghobrial's Degrees
- Doctorate Medicine Cairo University
Why Is Irene Ghobrial Influential?
(Suggest an Edit or Addition)According to Wikipedia, Irene Ghobrial is an American-Egyptian physician who is a professor at the Dana–Farber Cancer Institute and Harvard Medical School, where her research investigates the progression of multiple myeloma. She is interested in why certain patients with monoclonal gammopathy of undetermined significance and smoldering multiple myeloma develop B cell malignancies. She leads the Stand Up to Cancer multiple myeloma dream team.
Irene Ghobrial's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Biological properties of extracellular vesicles and their physiological functions (2015) (3453)
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc (2011) (2474)
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
- Ibrutinib in previously treated Waldenström's macroglobulinemia. (2015) (739)
- BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. (2013) (664)
- Targeting Apoptosis Pathways in Cancer Therapy (2005) (600)
- Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. (2005) (499)
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. (2007) (453)
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. (2009) (419)
- Genomic complexity of multiple myeloma and its clinical implications (2017) (354)
- MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. (2009) (320)
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma (2010) (307)
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. (2010) (306)
- Targeting the bone marrow microenvironment in multiple myeloma (2015) (283)
- Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. (2011) (278)
- Bone Marrow Microenvironment in Multiple Myeloma Progression (2012) (270)
- The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients (2020) (258)
- Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. (2009) (248)
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications (2014) (235)
- Engineered nanomedicine for myeloma and bone microenvironment targeting (2014) (233)
- A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma (2007) (219)
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop (2013) (216)
- Prognostic role of circulating exosomal miRNAs in multiple myeloma. (2017) (202)
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma (2008) (202)
- Bone marrow niches in haematological malignancies (2020) (199)
- Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. (2009) (199)
- IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. (2005) (191)
- Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia (2004) (190)
- Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. (2006) (181)
- Regulation of microRNAs in cancer metastasis. (2014) (180)
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
- Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. (2005) (175)
- C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. (2014) (172)
- Management of thalidomide toxicity. (2003) (169)
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
- Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. (2009) (164)
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. (2013) (164)
- Myeloma as a model for the process of metastasis: implications for therapy. (2012) (163)
- Waldenström macroglobulinemia (2004) (159)
- Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. (2014) (158)
- Mitochondrial metabolism promotes adaptation to proteotoxic stress (2019) (158)
- Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. (2005) (153)
- Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. (2009) (149)
- Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma (2018) (148)
- Differences between Early and Late Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Patients: Are They Two Different Diseases? (2005) (148)
- Proteomic analysis of mantle-cell lymphoma by protein microarray. (2005) (146)
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. (2007) (144)
- Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. (2010) (141)
- Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. (2017) (141)
- Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. (2009) (141)
- Metabolic signature identifies novel targets for drug resistance in multiple myeloma. (2015) (141)
- LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. (2012) (136)
- Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma (2018) (133)
- Chemokines in multiple myeloma. (2006) (133)
- Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. (2010) (133)
- Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia (2010) (132)
- 3D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening (2018) (127)
- Prognostic model for disease‐specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia (2006) (126)
- Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. (2011) (123)
- Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. (2011) (120)
- SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. (2008) (120)
- Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects (2011) (120)
- Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) (119)
- microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. (2010) (115)
- CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. (2015) (115)
- RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. (2009) (113)
- Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib (2012) (111)
- Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. (2007) (110)
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia (2010) (110)
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
- microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. (2009) (109)
- SDF-1 inhibition targets the bone marrow niche for cancer therapy. (2014) (109)
- Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. (2014) (108)
- The bone-marrow niche in MDS and MGUS: implications for AML and MM (2018) (107)
- Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. (2010) (104)
- The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. (2014) (102)
- Targeting NF-kappaB in Waldenstrom macroglobulinemia. (2008) (101)
- Role of endothelial progenitor cells in cancer progression. (2014) (100)
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma (2018) (97)
- Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. (2007) (96)
- P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. (2012) (93)
- 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. (2006) (92)
- Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. (2004) (92)
- Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era (2005) (91)
- Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma (2006) (91)
- Bortezomib in the front-line treatment of multiple myeloma (2008) (91)
- The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma (2017) (90)
- TAK‐228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia (2016) (89)
- The cancer glycome: carbohydrates as mediators of metastasis. (2015) (88)
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. (2011) (84)
- Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. (2019) (82)
- Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease (2012) (80)
- Targeting MYC in multiple myeloma (2017) (79)
- Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. (2010) (78)
- Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma (2007) (78)
- Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
- Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. (2008) (77)
- Defining the role of TORC1/2 in multiple myeloma. (2011) (77)
- The use of novel agents in the treatment of relapsed and refractory multiple myeloma (2009) (75)
- miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer (2014) (74)
- Kidney micro-organoids in suspension culture as a scalable source of human pluripotent stem cell-derived kidney cells (2019) (73)
- Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective study (2016) (72)
- Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. (2020) (69)
- Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia (2008) (68)
- The LIN28B/let-7 axis is a novel therapeutic pathway in Multiple Myeloma (2016) (67)
- Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. (2010) (65)
- Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations (2015) (65)
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020) (65)
- Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. (2006) (65)
- Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia (2020) (64)
- Dissecting racial disparities in multiple myeloma (2020) (63)
- Proteomic characterization of human multiple myeloma bone marrow extracellular matrix (2017) (63)
- Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ (2012) (61)
- Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia (2014) (59)
- Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression (2018) (58)
- Proteomic analysis of waldenstrom macroglobulinemia. (2007) (58)
- Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation (2014) (58)
- Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab (2018) (57)
- The Use of Silk as a Scaffold for Mature, Sustainable Unilocular Adipose 3D Tissue Engineered Systems (2016) (57)
- Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. (2016) (57)
- Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. (2015) (56)
- Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment (2008) (56)
- Extramedullary multiple myeloma (2013) (55)
- Pyk2 promotes tumor progression in multiple myeloma. (2014) (55)
- A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia (2013) (54)
- Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia (2017) (53)
- Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma (2005) (53)
- Multiple Myeloma and the Immune Microenvironment. (2017) (53)
- Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. (2019) (52)
- Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice (2016) (51)
- Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet‐Induced Obesity in Male Mice (2017) (51)
- Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia (2011) (50)
- Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. (2015) (49)
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
- A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma (2019) (48)
- Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. (2008) (47)
- Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. (2013) (47)
- The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia (2010) (46)
- Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia (2008) (46)
- Novel therapies in the treatment of multiple myeloma. (2009) (45)
- Targeting vasculogenesis to prevent progression in multiple myeloma (2016) (45)
- Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging. (2018) (43)
- Are you sure this is Waldenstrom macroglobulinemia? (2012) (43)
- How I treat smoldering multiple myeloma. (2014) (43)
- Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma (2017) (43)
- Genome instability in multiple myeloma (2020) (42)
- Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. (2016) (41)
- Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant (2008) (41)
- Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response (2004) (40)
- Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia (2007) (40)
- Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma (2014) (40)
- Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity. (2007) (39)
- Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma (2003) (39)
- The treatment of relapsed and refractory multiple myeloma. (2007) (39)
- The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia (2011) (38)
- High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. (2009) (38)
- The microenvironment in myeloma. (2019) (37)
- Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma (2014) (37)
- Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. (2011) (37)
- Management of myeloma-associated renal dysfunction in the era of novel therapies (2012) (37)
- Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. (2009) (37)
- Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. (2015) (36)
- Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy (2012) (36)
- Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays. (2005) (36)
- Extramedullary Waldenström macroglobulinemia (2015) (35)
- Monoclonal gammopathy of undetermined significance. (2019) (35)
- Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (2014) (35)
- Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma (2006) (35)
- Current use of monoclonal antibodies in the treatment of multiple myeloma (2018) (34)
- Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
- Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia (2010) (33)
- Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma (2018) (33)
- Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma (2019) (33)
- Plasma cell dyscrasias. (1982) (32)
- Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib (2008) (32)
- Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia (2011) (32)
- Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study (2014) (31)
- Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation (2018) (31)
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
- An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. (2003) (31)
- Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. (2018) (31)
- High‐dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosis (2004) (31)
- Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
- Exosomes in Tumor Angiogenesis. (2016) (30)
- Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia (2011) (30)
- Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine (2022) (30)
- The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action (2020) (30)
- Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
- A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia (2012) (29)
- Novel M-component based biomarkers in Waldenström's macroglobulinemia. (2011) (29)
- Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia (2009) (28)
- IgM myeloma: A multicenter retrospective study of 134 patients (2017) (28)
- Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche (2018) (28)
- Inhibitors of the ras oncogene as therapeutic targets. (2002) (28)
- Therapeutic options in patients with lymphoma and severe liver dysfunction. (2004) (28)
- Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. (2017) (28)
- Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma (2016) (27)
- Targeting SDF-1 in multiple myeloma tumor microenvironment. (2016) (27)
- A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia (2019) (26)
- Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial (2017) (26)
- Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma (2015) (25)
- Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1 (2014) (24)
- Tailored emulsion-templated porous polymer scaffolds for iPSC-derived human neural precursor cell culture (2017) (24)
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma (2018) (24)
- FGFR3 Is Overexpressed Waldenström Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation (2011) (24)
- Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia (2014) (24)
- Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation (2020) (24)
- IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM). (2006) (22)
- Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma (2017) (22)
- Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies (2016) (22)
- A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2018) (22)
- Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All (2020) (22)
- Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study (2013) (22)
- Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings (2011) (22)
- Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution (2016) (21)
- Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. (2006) (21)
- Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214) (2016) (21)
- Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study (2008) (21)
- The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia (2008) (20)
- Targeting NF-B in Waldenstrom macroglobulinemia (2008) (20)
- Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients (2010) (20)
- LYMPHOID NEOPLASIA C 1013 G / CXCR 4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma (2014) (20)
- Novel agents in the treatment of Waldenström's macroglobulinemia. (2007) (20)
- A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma (2011) (20)
- Update on therapeutic options in Waldenström macroglobulinemia (2009) (20)
- Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia (2009) (19)
- Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180. (2006) (19)
- Waldenström macroglobulinemia: from biology to treatment (2014) (19)
- Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia (2009) (19)
- Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy (2009) (19)
- Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing (2017) (19)
- Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies (2019) (19)
- Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. (2010) (18)
- Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (2014) (18)
- Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma (2013) (18)
- Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Waldenstrom Macroglobulinemia. (2021) (18)
- Management of relapsed and relapsed/refractory multiple myeloma. (2011) (18)
- Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib. (2007) (17)
- Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan‐class I PI3K inhibitor, buparlisib (2014) (17)
- Progression signature underlies clonal evolution and dissemination of multiple myeloma. (2020) (17)
- Established and Novel Prognostic Biomarkers in Multiple Myeloma. (2017) (17)
- Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM) (2014) (17)
- 3 D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening (2018) (17)
- Novel therapeutic avenues in myeloma: changing the treatment paradigm. (2007) (17)
- Molecular mechanisms of effectiveness of novel therapies in multiple myeloma (2013) (17)
- Proteomics analysis in post‐transplant lymphoproliferative disorders (2008) (16)
- Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia (2015) (16)
- Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. (2019) (16)
- Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma (2018) (16)
- Genomic Aberrations in Multiple Myeloma. (2016) (16)
- Multimodality imaging in amyloidosis (2012) (16)
- Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. (2019) (16)
- Fatal coronary artery disease after unrelated donor bone marrow transplantation. (2004) (16)
- Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology (2010) (16)
- Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. (2020) (16)
- Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo (2019) (16)
- Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. (2014) (16)
- Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. (2011) (16)
- A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2014) (15)
- Multiple myeloma: biology, standard therapy, and transplant therapy. (2009) (15)
- Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma (2008) (15)
- The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression (2013) (15)
- ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? (2009) (15)
- Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM) (2008) (15)
- Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. (2004) (15)
- Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia (2013) (15)
- Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstrom’s Macroglobulinemia (2013) (14)
- Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. (2009) (14)
- Biology, prognosis, and therapy of Waldenström Macroglobulinemia. (2015) (14)
- Cell Trafficking in Multiple Myeloma. (2012) (14)
- A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). (2006) (14)
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration (2021) (14)
- Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden (2015) (14)
- Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib (2013) (14)
- Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia (2018) (14)
- An In Vitro Differentiation Protocol for Human Embryonic Bipotential Gonad and Testis Cell Development (2020) (13)
- Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma (2019) (13)
- Choice of therapy for patients with Waldenstrom macroglobulinemia. (2013) (13)
- Renal cell carcinoma with acrometastasis and scalp metastasis. (2004) (13)
- An asymptomatic 61‐year‐old man with BCR‐ABL‐positive bone marrow following autologous transplantation for multiple myeloma (2010) (13)
- Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia (2012) (13)
- Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma (2010) (12)
- New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia (2011) (12)
- Novel treatment options for Waldenström macroglobulinemia. (2013) (12)
- Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia (2021) (11)
- The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib (2012) (11)
- New Frontiers in the Treatment of Multiple Myeloma (2006) (11)
- Emerging drugs in multiple myeloma (2007) (11)
- Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma (2014) (11)
- High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
- microRNA aberrations in Waldenström macroglobulinemia. (2013) (11)
- Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma. (2009) (11)
- Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis (2010) (11)
- Epigenetics in Multiple Myeloma. (2016) (11)
- Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience. (2008) (11)
- The bone marrow microenvironment in Waldenstrom macroglobulinemia (2011) (11)
- Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems. (2020) (10)
- Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (2022) (10)
- Pre-diagnosis dietary pattern and survival in patients with multiple myeloma. (2020) (10)
- Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia (2015) (10)
- Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. (2004) (10)
- Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia (2010) (10)
- Single-cell RNA sequencing: one step closer to the clinic (2021) (10)
- Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom’s Macroglobulinemia by Gene Expression Profiling. (2007) (10)
- Management of Relapsed and Relapsed/Refractory Multiple Myeloma (2011) (10)
- Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues (2007) (10)
- Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. (2019) (9)
- Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group (2019) (9)
- Front line treatment of elderly multiple myeloma in the era of novel agents (2008) (9)
- Bortezomib in the management of multiple myeloma (2009) (9)
- The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* (2012) (9)
- Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study. (2009) (9)
- Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. (2006) (8)
- Progression signature underlies clonal evolution and dissemination of Multiple Myeloma (2019) (8)
- MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study (2012) (8)
- Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. (2022) (8)
- Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes (2021) (8)
- Immunotherapy for hematological malignancies. (2019) (8)
- The bone marrow microenvironment in Waldenström macroglobulinemia. (2013) (8)
- Established and Novel Prognostic Biomarkers in Multiple Myeloma. (2017) (8)
- The road to cure in multiple myeloma starts with smoldering disease (2015) (8)
- Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma (2016) (7)
- Targeting the bone marrow in Waldenstrom macroglobulinemia. (2011) (7)
- Role of proteasome inhibition in Waldenström's macroglobulinemia. (2009) (7)
- Lack of Response to Vaccination in MGUS and Stable Myeloma. (2009) (7)
- American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma (2015) (7)
- Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma* (2014) (7)
- Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. (2018) (7)
- Upper Extremity Thrombosis Presenting as Medial Elbow Pain after Shoulder Arthroscopy (2014) (7)
- Targeted therapies in Waldenström macroglobulinemia. (2008) (7)
- Serum Galactomannan and (1→3)-β-d-Glucan Assays for Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia (2011) (6)
- Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia. (2006) (6)
- Rho-a and Rac-1 GTPases Play Major and Differential Roles in SDF1α- Induced Cell Adhesion and Chemotaxis in Multiple Myeloma. (2008) (6)
- The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome (2018) (6)
- Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia (2021) (6)
- Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma (2022) (6)
- Candidate genes of Waldenström’s macroglobulinemia: current evidence and research (2013) (6)
- Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib (2020) (6)
- Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis (2011) (6)
- Quantum mechanical ordering problem for observables which are linear in momentum (1975) (6)
- Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib (2010) (6)
- An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma. (2009) (6)
- A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia. (2009) (6)
- Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma (2011) (6)
- Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. (2009) (6)
- Revisiting treatment paradigms in high-risk smoldering multiple myeloma: out with the old, in with the new? (2013) (6)
- Autologous graft versus myeloma: it's not a myth. (2018) (6)
- Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera (2019) (6)
- Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. (2021) (6)
- Lower Doses of Bendamustine Are Not Associated with Lower Response Rates in Previously Untreated Patients with Waldenström Macroglobulinemia (2016) (5)
- Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation (2016) (5)
- Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia. (2009) (5)
- Bortezomib and Waldenstrom's macroglobulinemia. (2009) (5)
- Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia (2013) (5)
- miR-15a/16-1 deletion in activated B-cells promotes plasma cell and mature B-cell neoplasms. (2020) (5)
- A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety (2019) (5)
- Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. (2016) (5)
- Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (5)
- Bortezomib in Waldenstrom’s Macroglobulinemia (2011) (5)
- Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression (2013) (5)
- Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
- Does my patient with a serum monoclonal spike have multiple myeloma? (2012) (5)
- Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma (2023) (5)
- A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology (2013) (5)
- Novel therapeutic agents in Waldenström's macroglobulinemia. (2009) (5)
- The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
- ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. (2021) (5)
- Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias (2008) (4)
- High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study (2021) (4)
- Finding the right academic job. (2009) (4)
- The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (4)
- The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. (2022) (4)
- Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide (2011) (4)
- The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions (2017) (4)
- The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia. (2006) (4)
- Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia (2014) (4)
- Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment (2010) (4)
- The road to cure in multiple myeloma (2008) (4)
- Autonomous Calcium Signaling in Human and Zebrafish Podocytes Controls Kidney Filtration Barrier Morphogenesis (2021) (4)
- The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment (2014) (4)
- Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. (2012) (4)
- Lenalidomide Has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis. (2005) (4)
- Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma (2015) (4)
- A novel in vivo model for studying conditional dual loss of BLIMP‐1 and p53 in B‐cells, leading to tumor transformation (2017) (4)
- Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia (2011) (4)
- Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom’s Macroglobulinemia. (2007) (4)
- Author Correction: Mitochondrial metabolism promotes adaptation to proteotoxic stress (2019) (4)
- Waldenstrom macroglobulinemia. (2008) (4)
- Clinical Controversies in the Management of Smoldering Multiple Myeloma. (2020) (4)
- Imatinib Mesylate (Gleevec®) Is Active in Relapsed/Refractory Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140. (2006) (4)
- Circulating exosomal microRNAs are critical prognostic markers independent of cytogenetics and International Staging System in Multiple Myeloma (2015) (4)
- Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia (2008) (4)
- Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia. (2007) (4)
- The Treatment of Multiple Myeloma Patients Not Eligible for Asct (2010) (4)
- In Vivo Monitoring of Rare Circulating Tumor Cell and Cluster Dissemination in a Multiple Myeloma Xenograft Model (2019) (4)
- Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes (2021) (4)
- BELLINI: a renaissance for an era of precision therapy in multiple myeloma. (2020) (4)
- Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression (2017) (3)
- Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (2015) (3)
- RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia. (2009) (3)
- Development of an Antibody-Targeted Nanoparticle for Early Detection of Minimal Residual Disease in Multiple Myeloma (2017) (3)
- Quantization as deformation theory (1976) (3)
- Low Expression Of The FUCA1 Gene Is An Adverse Prognostic Factor In Myeloma and Combined With High Sialyltransferase Gene Expression Identifies Patients At Increased Risk Of Early Disease Progression and Death (2013) (3)
- Founding Precision Therapy in 1q-Amplified Multiple Myeloma (2018) (3)
- In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches (2012) (3)
- Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD). (2005) (3)
- Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential (2018) (3)
- Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. (2019) (3)
- Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model (2014) (3)
- Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM. (2006) (3)
- In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis. (2007) (3)
- A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma (2014) (3)
- Serum Free Light Chain in Waldenstrom Macroglobulinemia. (2006) (3)
- The High Risk for Symptomatic Hyperviscosity in Patients with High Serum IgM Levels Can be Used to Support Initiation of Treatment in Waldenström Macroglobulinemia (2016) (3)
- The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom’s Macroglobulinemia. (2006) (3)
- Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma (2010) (3)
- Molecular Analysis Of Circulating Tumor Cells Identifies Mutations That Are Distinct From Those Present In The Bone Marrow Of Patients With Multiple Myeloma (2013) (3)
- The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy. (2004) (3)
- Novel agents in Waldenström macroglobulinemia. (2011) (3)
- Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results. (2007) (3)
- Novel agents in Waldenstrom Macroglobulinemia. (2010) (3)
- Bortezomib and Waldenstrom's macroglobulinemia (2009) (3)
- In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma (2016) (2)
- Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM). (2015) (2)
- Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways (2013) (2)
- Bone marrow niche in multiple myeloma and its precursor states (2019) (2)
- Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis in multiple myeloma (MM) (2005) (2)
- Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients (2012) (2)
- Aspirin Use and Survival in Multiple Myeloma Patients (2018) (2)
- Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. (2007) (2)
- CXCR4 Is a Regulator Of Disease Involvement Of Extramedullary Myeloma Confirmed By a Novel Mouse Model For Extramedullary Disease (2013) (2)
- Recent Advances in Angiogenesis and Antiangiogenesis (2018) (2)
- Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma. (2010) (2)
- The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstrom’s Macroglobulinemia. (2006) (2)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
- Targeting a Myeloma Translocation for the First Time: The t(11;14) Journey (2018) (2)
- Metabolic Signature Identi fi es Novel Targets for Drug Resistance in Multiple Myeloma (2015) (2)
- Hevylite®, a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia (2010) (2)
- Kidney Organoids Generated Using an Allelic Series of NPHS2 Point Variants Reveal Distinct Intracellular Podocin Mistrafficking (2022) (2)
- Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM). (2007) (2)
- Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial (2011) (2)
- Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma. (2013) (2)
- Driver Mutation in Waldenstrom's Macroglobullinemia and Their Clonal Heterogeneity during Progression and Relapse (2016) (2)
- Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. (2011) (2)
- Role of TORC1 and TORC2 in Multiple Myeloma (2011) (2)
- Founding precision therapy for 1q-amplified multiple myeloma (2019) (2)
- Waldenström's Macroglobulinemia: new therapeutic options (2008) (2)
- New Therapeutic Approaches for Waldenstrom Macroglobulinemia. (2010) (2)
- The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM). (2007) (2)
- miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer (2014) (2)
- The role of miRNAs in plasma cell dyscrasias. (2014) (2)
- Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM). (2005) (2)
- Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma (2010) (2)
- Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). (2014) (2)
- Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (2)
- Epigenetics in Waldenström's macroglobulinemia. (2010) (2)
- The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. (2021) (2)
- Inflammatory stromal cells in the myeloma microenvironment (2021) (2)
- Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia (2011) (2)
- Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: A prospective cohort study (2021) (2)
- Abstract 2060: microRNA-dependent modulation of histone acetylation in Waldenstrom's Macroglobulinemia (2010) (2)
- Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques. (2005) (2)
- Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia (2019) (2)
- CXCR7 Regulates SDF-1 Induced Adhesion and Homing in Multiple Myeloma. (2008) (2)
- MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. (2011) (2)
- A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma (2021) (2)
- Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia. (2009) (2)
- CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells (2012) (1)
- LYMPHOID NEOPLASIA Pyk2 promotes tumor progression in multiple myeloma (2014) (1)
- Novel Options of Therapy in Waldenstro¨m Macroglobulinemia (2007) (1)
- The bone marrow niche in Waldenström's macroglobulinemia. (2011) (1)
- Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM). (2007) (1)
- Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma (2014) (1)
- Regular Aspirin Use and Mortality in Patients with Multiple Myeloma (2021) (1)
- A Rationally Designed Novel Polymer for Safe and Synergistic Delivery of High Dose Bortezomib, Pomalidomide/Lenalidomide, and Dexamethasone for Multiple Myeloma (2018) (1)
- Epigenomics in Waldenstrom's macroglobulinaemia. (2016) (1)
- MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu. (2009) (1)
- Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis (2019) (1)
- Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression (2014) (1)
- Molecular Pathways in Growth and Survival: Epigenomics (2017) (1)
- Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden (2016) (1)
- Immunomodulatory therapy improves outcome in multiple myeloma patients with clonal hematopoiesis (2019) (1)
- A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease (2018) (1)
- The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM). (2005) (1)
- Simple Soft Tissue Biceps Tenodesis (2022) (1)
- Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study (2023) (1)
- IgM Myeloma: A Multicenter Retrospective Study of 159 Patients (2016) (1)
- TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström’s Macroglobulinemia (2008) (1)
- On quantization of tensor fields (1978) (1)
- Mass cytometry staining for human bone marrow clinical samples (2022) (1)
- Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation (2022) (1)
- Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. (2016) (1)
- Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma (2021) (1)
- Nanoparticle Design For Bone-Specific Chemotherapy and Microenvironmental Targeting In Multiple Myeloma (2013) (1)
- TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application (2008) (1)
- Hypoxia Induces Drug Resistance In Multiple Myeloma (2013) (1)
- Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia (2016) (1)
- A High-Throughput Drug Screen Reveals a Novel Compound Class That Significantly Depletes IRF4 Expression in Multiple Myeloma (2019) (1)
- B622 Rho-A and Rac-1 GTPases in Multiple Myeloma (2009) (1)
- In Vivo Analysis of Clonal Evolution of Multiple Myeloma (2016) (1)
- A Next Generation Liquid Biopsy Approach for Multiple Myeloma (2020) (1)
- Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma, (2011) (1)
- Long-term follow-up of exceptional responders on the phase II trial of weekly bortezomib and rituximab in untreated and relapsed patients with waldenstrom's macroglobulinemia. (2016) (1)
- Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma (2015) (1)
- The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM). (2005) (1)
- Plasma cell disorders (2013) (1)
- Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia. (2006) (1)
- Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma (2016) (1)
- The Role of the CXCR4 Inhibitor AMD3100 in Multiple Myeloma (MM). (2005) (1)
- Migration and Homing in Multiple Myeloma (2013) (1)
- CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma (2012) (1)
- Response: Sensitization initiated (2009) (1)
- In Search of Missed Tumors: Next-Generation Sequencing for Minimal Residual Disease Detection in Multiple Myeloma Comes of Age (2018) (1)
- Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma (2013) (1)
- Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
- The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258. (2009) (1)
- Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis (2021) (1)
- Regulation of Histone Deacetylase in Waldenström Macroglobulinemia (2008) (1)
- Abstract PR14: In vivo targeting of stromal-derived factor-1 as a strategy to prevent myeloma cell dissemination to distant bone marrow niches (2015) (1)
- Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy (2010) (1)
- The emerging role of novel therapeutic agents in the management of patients with multiple myeloma (2006) (1)
- Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges (2022) (1)
- Abstract 4855: Proteomic characterization of the extracellular matrix in multiple myeloma (2014) (1)
- Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia. (2009) (1)
- Individualizing treatment for Waldenstrom’s macroglobulinemia (2009) (1)
- Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression (2018) (1)
- Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology (2021) (1)
- Bone marrow biopsy in low-risk MGUS patients reveals a novel MGUS-like Smoldering multiple myeloma risk group (2019) (1)
- Team Work Matters: Dual Inhibition Puts Non-Hodgkin Lymphoma Under Siege (2014) (1)
- Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. (2019) (1)
- Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination (2014) (1)
- The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma (2011) (1)
- Regular Aspirin Use and Mortality in Multiple Myeloma Patients. (2021) (1)
- Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma (2015) (1)
- Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders: BCL2 as a prognostic marker (2007) (1)
- Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma (2022) (1)
- The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche (2019) (0)
- The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia. (2007) (0)
- Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia (2010) (0)
- Abstract 640: Genome sequencing of circulating multiple myeloma cells for minimally invasive molecular characterization of precursor disease pathology (2022) (0)
- Cholesterol Regulation and Statin Therapy in Patients with Waldenstrom's Macroglobulinemia. (2009) (0)
- Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib (2014) (0)
- RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma (2011) (0)
- B526 PKC412, Small-Molecule Tyrosine Kinase Inhibitor, Regulates Survival in Waldenström Macroglobulinemia (2009) (0)
- Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix (2014) (0)
- Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy (2004) (0)
- 1 Targeting NF-κ B in Waldenstrom Macroglobulinemia (2008) (0)
- Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia. (2005) (0)
- Prevalence of Monoclonal Gammopathies Including an Age-Related Monoclonal Gammopathy of Indeterminate Potential (MGIP) in a Racially Diverse US Population Screened by Mass Spectrometry (2021) (0)
- Abstract 796: Altered immune response to vaccination in patients with plasma cell premalignancy (2023) (0)
- Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma (2012) (0)
- Abstract A82: Prognostic relevance and genomic profile of circulating tumor cells in multiple myeloma (2015) (0)
- The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia (2017) (0)
- A534 Perifosine: Final Results of a Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia (2009) (0)
- Inhibition of mitochondrial ferredoxin 1 (FDX1) prevents adaptation to proteotoxic stress (2018) (0)
- Cell trafficking in multiple myeloma (2011) (0)
- In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment (2008) (0)
- Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM). (2004) (0)
- Acute Lymphoblastic Leukemia (ALL) as a Second Primary Malignancy (SPM) After Multiple Myeloma (MM): Secondary Clonally Related Neoplasm or Therapy-Related Leukemia? (2017) (0)
- Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment. (2009) (0)
- myeloma IL-3 is a potential inhibitor of osteoblast differentiation in multiple (2013) (0)
- Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM). (2005) (0)
- A Case-Control Epidemiological Study Of Waldenstrom Macroglobulinemia (2013) (0)
- Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma (2016) (0)
- Proteomic Analysis of Multiple Myeloma Identifies Upregulation of CRIK Protein, a Novel Protein Regulating Migration and Adhesion (2008) (0)
- Update on Waldenström's macroglobulinemia. (2013) (0)
- The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment. (2009) (0)
- Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma (2021) (0)
- Abstract 3582: Single-cell RNA-sequencing for immune profiling of SARS-CoV2 vaccine response in healthy individuals and patients with precursor plasma cell malignancies (2022) (0)
- Abstract A106: Mechanisms underlying extra-medullary myeloma development (2015) (0)
- Word Count : 4113 Abstract word count : 245 Number of Figures : 7 Number of Supplemental Figures : 2 Number of Supplemental Tables : 1 Number of Supplemental Movies : 0 (2017) (0)
- Cancer Therapy: Preclinical Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia (2011) (0)
- Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes (2021) (0)
- Roundabout 1 (ROBO1) Mediates Multiple Myeloma Survival and Interaction with the Bone Marrow Microenvironment (2019) (0)
- Abstract #1393: MicroRNA in the biology, prognosis and therapy of Waldenstrom macroglobulinemia (2009) (0)
- Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease. (2009) (0)
- Current Practices in Managing Multiple Myeloma (MM): Elucidating Educational Needs of Hematology/Oncology Clinicians (2017) (0)
- and inhibits immune function in multiple myeloma Elevated IL-17 produced by Th 17 cells promotes myeloma cell growth (2010) (0)
- Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma (2011) (0)
- Abnormal Expression of TRAF Adapter Proteins in Waldenstrom’s Macroglobulinemia. (2006) (0)
- Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders (PTLD), BCL2 Is a Poor Prognostic Marker in PTLD. (2006) (0)
- OAB-028: Single-cell dissection of bone marrow and peripheral blood immune cells in a large cohort of patients with smoldering multiple myeloma at diagnosis and post-therapy (2022) (0)
- Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo (2013) (0)
- Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma (2012) (0)
- The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma (2008) (0)
- Redefining Risks in Multiple Myeloma is Still a Work in Progress (2018) (0)
- B540 The Effect of Insulin-Like Growth Factor-1 in Waldenström Macroglobulinemia (2009) (0)
- The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs. (2013) (0)
- The rise of molecular glues and bifunctional compounds (2022) (0)
- Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM). (2009) (0)
- Roundabout 1 (ROBO1)/SLIT2 Is a Novel Signaling Pathway in Multiple Myeloma Promoting Survival and Bone Marrow Niche Interaction (2016) (0)
- Early Response Using Serum Immunoglobulin Free Light Chain (sFLC) Measurement Predicts Response to Therapy in Waldenstrom Macroglobulinemia (WM) (2008) (0)
- Abstract IA07: Multiple myeloma as a model of bone metastasis. (2015) (0)
- Dual PI3K and mTOR Inhibition in Waldenstrom Macroglobulinemia (2008) (0)
- Germinal Center-Derived Lymphomas and Plasmacytomas in Mice with Targeted Deletion of MiR-15a/16-1 in Activated B Cells (2016) (0)
- Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM (2014) (0)
- The Effect of Insulin-Like Growth Factor 1 on Waldenstrom Macroglobulinemia (2008) (0)
- Stand up to Cancer: Citizen Science to Discover Predictors of Monoclonal Gammopathy of Undetermined Significance (MGUS) and MGUS Progression (2018) (0)
- Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition. (2005) (0)
- Abstract A38: A novel clinical-grade liquid biopsy platform for multiple myeloma (2020) (0)
- Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis (2016) (0)
- Single-cell multi-omics defines the cell-type specific impact of splicing aberrations in human hematopoietic clonal outgrowths (2022) (0)
- Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients (2017) (0)
- Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo (2018) (0)
- P-055: Monitoring the emergence of multiple myeloma high-risk subclones with whole-genome sequencing of circulating tumor cells (2022) (0)
- The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia (2011) (0)
- Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma (2013) (0)
- A Novel Real-Time In Vivo Homing Model of Multiple Myeloma. (2006) (0)
- Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD). (2005) (0)
- Epigenetic regulation of gene expression in progression of multiple myeloma (2019) (0)
- PKC412, a Small Molecule Tyrosine Kinase Inhibitor, Regulates Survival and Proliferation Pathways in Waldenström Macroglobulinemia (2008) (0)
- Cell trafficking and tumor metastasis - two sides of the same coin (2012) (0)
- Can We Vaccinate Our Way Out of Multiple Myeloma Progression (2018) (0)
- LNA Anti-Microrna-155: a Novel Therapeutic Strategy In Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia (2010) (0)
- L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to Enhanced Sensitivity to Bortezomib (2011) (0)
- Pomalidomide for the treatment of relapsed and refractory multiple myeloma (2014) (0)
- Multiple Myeloma and the Bone Marrow Niche (2015) (0)
- Dissecting racial disparities in multiple myeloma (2020) (0)
- Abstract 5277: Humoral SARS-CoV-2 response in asymptomatic precursor plasma cell dyscrasia patients: IMPACT study results (2022) (0)
- A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts (2020) (0)
- Thalidomide in multiple myeloma in the elderly (2009) (0)
- Diagnostic TR-FRET assays for detection of antibodies in patient samples (2023) (0)
- Trafficking of Multiple Myeloma Cells: What Regulates Homing, Adhesion, and Mobilization of Multiple Myeloma to and from the Bone Marrow Niches (2009) (0)
- Biological Sequelae of TRAF2 Downregulation in Waldenstrom Macroglobulinemia Cells. (2007) (0)
- The PROMISE Study: A Nationwide Project for Predicting the Progression of Developing Myeloma in a High-Risk Screened Population (2019) (0)
- P-150: Quality of life, psychological distress, and prognostic awareness in patients with Multiple Myeloma (2021) (0)
- Author Correction: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma (2023) (0)
- Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients (2021) (0)
- Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma (2010) (0)
- Similar Dreams, Different Journeys (2011) (0)
- MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia, (2011) (0)
- The Moving Target of When to Treat on the Myeloma Spectrum (2020) (0)
- Perceptions of prognosis in caregivers of multiple myeloma (MM) patients. (2021) (0)
- Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma (2013) (0)
- P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma (2022) (0)
- LYMPHOID NEOPLASIA The sialyltransferase ST3GAL6 in fl uences homing and survival in multiple myeloma (2014) (0)
- Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma (2023) (0)
- A Single Surviving Cancer Cell Reflects the Mutational Landscape of Relapsed Multiple Myeloma (2020) (0)
- Abstract LB217: ROBO1 promotes homing, dissemination, and survival of multiple myeloma within the bone marrow microenvironment (2021) (0)
- Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells (2010) (0)
- Quantified Morphology in Diagnosis of Hematologic Malignancies (2020) (0)
- Multiple Myeloma-Derived Bone-Marrow Mesenchymal Stem Cells: Microrna-, Gene Expression-Profiling and Functional Characterization (2012) (0)
- Gene Transcriptional Activity Analysis in the 6q Region in Waldenstrom Macroglobulinemia (WM) Using ChIP-on-Chip Technology (2008) (0)
- Abstract B62: Stroma-derived exosomes mediate progression in multiple meyloma (2015) (0)
- Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients (2021) (0)
- Abstract 2986: Study of genetic dependencies associated with 1q-amplified multiple myeloma (2019) (0)
- Exosomes in Hematologic Malignancies (2014) (0)
- Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/β-Catenin Signaling Pathway (2013) (0)
- Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule (2018) (0)
- In vivo modeling of clonal competition using CRISPR-based gene editing reveals novel fitness variables in multiple myeloma (2018) (0)
- SOLVING CLINICAL PROBLEMS IN BLOOD DISEASES An asymptomatic 61-year-old man with BCR-ABL -positive bone marrow following autologous transplantation for multiple myeloma (2010) (0)
- Molecular Modification of the Microenvironment by the Tumor Clone (2014) (0)
- P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS (2015) (0)
- Whole-exome Sequencing and Ultra Low Pass-whole Genome Sequencing of cfDNA and CTCs Enable a Comprehensive Mutational Landscape of Multiple Myeloma (2017) (0)
- Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy. (2004) (0)
- Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy. (2004) (0)
- Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy (2022) (0)
- Abstract 679: Dual conditional loss of BLIMP-1 and p53 in B-cells drives B-cell lymphomagenesis (2016) (0)
- B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. (2022) (0)
- P-021: 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibodydependent cell cytotoxicity (2022) (0)
- New Approaches to Multiple Myeloma (2018) (0)
- The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia (2010) (0)
- Sa1681 Inhibition of the Prostaglandin EP1 Receptor Suppresses Colon Cancer Cell Invasion and Metastasis. (2013) (0)
- The Multiple Myeloma Bone Marrow Microenvironment (2012) (0)
- Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma. (2009) (0)
- The Microbiome: A New Variable in Multiple Myeloma Disease Progression (2019) (0)
- A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (2021) (0)
- Regular Aspirin Use and Mortality in Multiple Myeloma Patients (2021) (0)
- Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability (2022) (0)
- A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. (2009) (0)
- A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma (2021) (0)
- A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (2018) (0)
- Reply to F.D. Leonard. (2019) (0)
- Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells. (2009) (0)
- NANOPARTICULES DIRIGÉES CONTRE UN ANTIGÈNE DE MATURATION DES LYMPHOCYTES B (BCMA) (2018) (0)
- XBP1s: Getting to the Roots of Multiple Myeloma (2019) (0)
- How I Treat How I treat smoldering multiple myeloma (2014) (0)
- From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma (2009) (0)
- Proteasome inhibition regulates survival and homing in Waldenstrom Macroglobulinemia (WM) (2008) (0)
- Abstract 3651: Obesity, metabolic comorbidities, and lifestyle factors and their association with monoclonal gammopathies in a high-risk screened population: Results of the PROMISE study (2022) (0)
- P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results (2021) (0)
- MYC Overexpressing Multiple Myeloma Are Dependent on GLS1 (2019) (0)
- Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains (2017) (0)
- Type I interferons augment regulatory T cell polarization in concert with ancillary cytokine signals (2023) (0)
- Experimental Design & Analysis of Protein Array Data: Applying Methods from cDNA Arrays. (2004) (0)
- PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM). (2009) (0)
- Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom’s Macroglobulinemia, the Role of the ERK and PKC Pathways. (2006) (0)
- OAB-036: The PANGEA model: dynamic modeling for personalized prediction of precursor disease progression to multiple myeloma (2022) (0)
- Intensification and consolidation therapy in multiple myeloma in the current era. (2020) (0)
- Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM (2022) (0)
- RewIRE(1α)ing the Unfolded Protein Response in Multiple Myeloma (2019) (0)
- Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy. (2004) (0)
- Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution (2013) (0)
- Abstract IA10: Liquid biopsies as biomarkers of disease progression in multiple myeloma (2020) (0)
- Questions from the Community Clinical Investigators Provide Their Perspectives on Challenging Issues and Ongoing Research in the Management of Multiple Myeloma (2016) (0)
- The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma (2011) (0)
- MinimuMM-seq: Genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. (2022) (0)
- IgL Translocations for Risk Stratification in Multiple Myeloma (2019) (0)
- Inhibition of c-Myc Expression and Function in Hematologic Malignancies (2011) (0)
- A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish (2015) (0)
- Bispecific Antibodies in Multiple Myeloma: Do These T cell-Recruiting Antibodies Make a Difference? (2020) (0)
- miRNA analysis between malignant and benign tissue and circulating exosomes (CE) in patients (pts) with tongue squamous cell carcinoma. (2013) (0)
- Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma. (2010) (0)
- Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma (2022) (0)
- P-134: Quality of life, psychological distress, and prognostic awareness in caregivers of patients with Multiple Myeloma (2021) (0)
- Molecular Mechanisms Involved in Homing and Migration of Plasma Cells in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway. (2004) (0)
- Choice of Therapy for Patients With (2012) (0)
- Cancer Therapy : Preclinical Mechanisms of Activity of the TORC 1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia (2012) (0)
- Regulation of the New CXCR7 Receptor in Plasma Cell Dyscrasias. (2007) (0)
- Identification of An Atypical Paraprotein with Inconsistent M-Spike Quantitation in Four Patients with Waldenstrom’s Macroglobulinemia (2008) (0)
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant (2020) (0)
- Proteomic Analysis of Post Transplant Lymphoproliferative Disorders (PTLD) Using Nanoscale Protein Microarray Techniques. (2005) (0)
- The impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction (2013) (0)
- Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients (2013) (0)
- Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia (2009) (0)
- Progression Risk-Based Classification of Asymptomatic Waldenström Macroglobulinemia (2018) (0)
- Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success (2015) (0)
- Diagnostic and prognostic use of FDG-PET scans in Waldenstrom's macroglobulinemia. (2009) (0)
- Resveratrol Exerts AntiproliferativeActivity and Induces Apoptosis inWaldenstro« m’s Macroglobulinemia (2008) (0)
- Extramedullary Disease In Waldenstrom’s Macroglobulinemia (2013) (0)
- Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma (2009) (0)
- Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study (2022) (0)
- Characterization of Waldenström Macroglobulinemia Subtypes using Global Gene Expression Profiling. (2004) (0)
- Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma (2012) (0)
- MicroRNA Signature in Waldenstrom Macroglobulinemia (2008) (0)
- B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma (2021) (0)
- CHALLENGES IN THE MANAGEMENT OF HIGH-RISK MULTIPLE MYELOMA (2023) (0)
- Promising Preclinical Results for Immunotherapy in Multiple Myeloma (2020) (0)
- Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma (2014) (0)
- Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM) (2018) (0)
- Immunotherapy in Multiple Myeloma: The Era of CAR T Cell Therapy (2018) (0)
- Repositioning the Repurposed Drug, a Structural Study of Thalidomide Analogs (2019) (0)
- When Does Monoclonal Gammopathy Acquire Significance (2018) (0)
- myeloma cells with the bone marrow microenvironment P-selectin glycoprotein ligand regulates the interaction of multiple (2012) (0)
- Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM). (2008) (0)
- Would the real myeloma cell please stand up? (2012) (0)
- Tu1677 Upregulation of Fas Ligand Expression Promotes Colon Cancer Cell Migration and Metastasis In Vitro and In Vivo (2014) (0)
- Abstract 2240: Genomic profiling of smoldering multiple myeloma classifies distinct molecular groups (2021) (0)
- Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma (2016) (0)
- Abstract 2142: The nuclear export protein CRM1 (XPO1) regulates multiple myeloma cell growth, osteoclastogenesis, and myeloma-induced osteolysis. (2013) (0)
- The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenström Macroglobulinemia (2008) (0)
- B527 The Tyrosine Kinase Src Regulates Adhesion and Survival in Waldenström Macroglobulinemia (2009) (0)
- ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. (2021) (0)
- CXCR 4 Regulates Extra-M edullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation Graphical (2015) (0)
- Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (2022) (0)
- Abstract 802: Cytokine profiles in bone marrow supernatant and peripheral blood of patients with multiple myeloma and Waldenström's macroglobulinemia (2011) (0)
- Cancer Therapy : Preclinical FGFR 3 Is Overexpressed Waldenstr € om Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation (2011) (0)
- Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells (2014) (0)
- Bone marrow niches in haematological malignancies (2020) (0)
- Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia (2019) (0)
- Debate - Change Therapy for High/Low Risk Patients - No (2015) (0)
- microRNA aberrations and their role in supporting hematologic malignancies. (2014) (0)
- Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology (2022) (0)
- MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma (2015) (0)
- CancerCellDisseminationandHoming to theBone Marrow in a Zebra fi sh Model (2016) (0)
- Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway. (2004) (0)
- Perforation of the Glenoid Neck During Arthroscopic Anterior and Posterior Bankart Repair: A Cadaveric Study (SS-08) (2012) (0)
- Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study (2022) (0)
- Mass Spectrometry-Detected Monoclonal Gammopathy of Undetermined Significance is Associated with Obesity and Other Novel Modifiable Risk Factors: Results of the Promise Study (2022) (0)
- Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race (2022) (0)
- Abstract 641: Single-cell RNA sequencing of rare circulating tumor cells in precursor myeloma patients reveals molecular underpinnings of tumor cell circulation (2022) (0)
- Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa (2022) (0)
- On the quantization of tensor field. II (1983) (0)
- In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma (2022) (0)
- Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma (2022) (0)
- High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients (2022) (0)
- Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells (2022) (0)
- Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis (2022) (0)
This paper list is powered by the following services:
Other Resources About Irene Ghobrial
What Schools Are Affiliated With Irene Ghobrial?
Irene Ghobrial is affiliated with the following schools:
